Counselors in Limon, CO Accepting Medicare

6 Counselors found. Showing 1 - 6

Ray A Kessler, PH.D Counselor Medicare: Not Enrolled in Medicare Practice Location: 820 1st St., Limon, CO 80828 Phone: 719-775-2367    Fax: 719-775-2365

Mr. Steven Paul Gilbertson, MA Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 606 Main Street, Limon, CO 80828 Phone: 719-775-2313    Fax: 719-775-2315

Robert Robertson Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 606 Main Street, Limon, CO 80828 Phone: 970-522-4549    Fax: 970-522-4211

Ms. Patricia Irene Thompson, M.A., C.M.T. Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 606 Main Street, Limon, CO 80828 Phone: 719-775-2313    Fax: 719-775-2315

Carrie Glidden-lewis, MA Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 820 1st Street, Limon, CO 80828 Phone: 970-522-4549    Fax: 970-522-4211

Roxanne Upshaw, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 820 1st St., Limon, CO 80828 Phone: 719-775-2367    Fax: 719-775-2365

News Archive

Anticipatory signals in eye movements can help measure attentive capacity, learning with greater precision

How can we tell what a person is thinking? Sometimes, it is enough to observe one's behavior, for example, how they respond to a stimulus in the environment.

GlaxoSmithKline to make clinical trial data available to other researchers

GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs."

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

Preliminary Phase 3 clinical study results of T-Pred released

ISTA Pharmaceuticals, Inc., today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

Read more Medical News

› Verified 5 days ago